← Precigen, Inc. (PGEN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Precigen, Inc. (PGEN)
Pharmaceutical Preparations · market cap $2.7B · as of 2026-07-17
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Precigen, Inc. (NASDAQ: PGEN) is a Germantown, MD-based clinical-stage biotech (formerly Intrexon) applying synthetic biology to cell and gene therapy. Its lead assets are PRGN-2009 in combination with pembrolizumab (Phase 2, cervical cancer) and PRGN-2012 (Phase 2, recurrent respiratory papillomatosis). At ~$5.12/share and a $1.825B market cap, the company carries severe near-term financial distress: $7.5M cash, approximately 0.5 months of runway, and $86M in net debt.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| PRGN-2009 plus Pembrolizumab | Phase 2 | Cervical Cancer |
| PRGN-2012 - Phase I; Dose Level 1 | Phase 2 | Recurrent Respiratory Papillomatosis |
Price & technical context
3-month
+47.9%
6-month
+110.2%
12-month
+147.9%
52-wk range
$3.10–$8.56
vs 50-day MA
+17.9%
vs 200-day MA
+65.5%
Realized vol
77.2%
Max drawdown
-42.4%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PGEN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.